Brief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
16/09/2026 07:07
BRIEF-BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan Sept 16 (Reuters) - BioArctic AB (publ) BIOAb.ST:
LEQEMBI® PEN SUBCUTANEOUS FORMULATION APPROVED IN JAPAN
Source text: ID:nWkrbbzXRh
Further company coverage: [BIOAb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln